Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 3Withdrawn 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 152Neoplasms 108Carcinoma, Non-Small-Cell Lung 83Colorectal Neoplasms 81Prostatic Neoplasms 80Lung Neoplasms 71Leukemia, Myeloid, Acute 48Carcinoma, Hepatocellular 48Pancreatic Neoplasms 45Neoplasm Metastasis 39Multiple Myeloma 37Recurrence 34Triple Negative Breast Neoplasms 29Squamous Cell Carcinoma of Head and Neck 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Melanoma 27Glioblastoma 27Head and Neck Neoplasms 25Brain Neoplasms 25Uterine Cervical Neoplasms 24Stomach Neoplasms 24Rectal Neoplasms 24Ovarian Neoplasms 24Small Cell Lung Carcinoma 22Carcinoma, Renal Cell 20Lymphoma, B-Cell 19Lymphoma, Follicular 18Lymphoma 18Endometrial Neoplasms 18Glioma 17

Interventions

atezolizumab 1PM 01183 1Etoposide 1EC regimen 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Small Cell × 90 days × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡